样式: 排序: IF: - GO 导出 标记为已读
-
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-15 Mats Christian Højbjerg Lassen, John W. Ostrominski, Silvio E. Inzucchi, Brian L. Claggett, Ian Kulac, Pardeep Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Mikhail N. Kosiborod, Carolyn S.P. Lam, Felipe A. Martinez, Sanjiv J. Shah, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, Kieran F. Docherty, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan
-
On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HF Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-15 Veraprapas Kittipibul, Robert J. Mentz, Robert M. Clare, Daniel M. Wojdyla, Kevin J. Anstrom, Eric L. Eisenstein, Andrew P. Ambrosy, Parag Goyal, Hal A. Skopicki, Fassil Ketema, Dong-Yun Kim, Patrice Desvigne-Nickens, Bertram Pitt, Eric J. Velazquez, Stephen J. Greene
The TRANSFORM-HF trial demonstrated no significant outcome differences between torsemide and furosemide following hospitalization for heart failure (HF), but may have been impacted by non-adherence to the randomized diuretic. The current study sought to determine the treatment effect of torsemide versus furosemide using an on-treatment analysis inclusive of all randomized patients except those confirmed
-
Pushing the limits of natriuresis for poor kidneys in acute heart failure? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Frederik H. Verbrugge
-
Insulin‐like growth factor binding protein‐7 in heart failure: The challenge of moving from risk prediction to a biomarker‐guided management Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Giorgia Panichella, Daniela Tomasoni, Alberto Aimo
-
Letter regarding the article ‘Subclinical systolic dysfunction in genotype‐positive phenotype‐negative relatives of dilated cardiomyopathy patients: A systematic review and meta‐analysis’ Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Arif Albulushi, Ghalib Al Hinai, Nadya Al Matrooshi
-
Reply to the letter regarding the article ‘Subclinical systolic dysfunction in genotype‐positive phenotype‐negative relatives of dilated cardiomyopathy patients: A systematic review and meta‐analysis’ Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Andrea Faggiano, Elisa Gherbesi, Eleonora Gnan, Alessia Paldino, Marco Merlo, Gianfranco Sinagra, Stefano Carugo
-
What we claim to do and what we really do – a discrepancy in heart failure treatment Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Birgit Assmus, Samuel Sossalla
-
Mitral regurgitation and heart failure with preserved ejection fraction: Should we treat the muscle, the valve, or both? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Mauro Riccardi, Barry A. Borlaug, Riccardo M. Inciardi
-
Frailty according to the 2019 HFA‐ESC definition in patients at risk for advanced heart failure: Insights from the HELP‐HF registry Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Alessandro Villaschi, Mauro Chiarito, Matteo Pagnesi, Davide Stolfo, Luca Baldetti, Carlo Mario Lombardi, Marianna Adamo, Ferdinando Loiacono, Antonio Maria Sammartino, Giada Colombo, Daniela Tomasoni, Riccardo Maria Inciardi, Marta Maccallini, Gaia Gasparini, Marco Montella, Stefano Contessi, Daniele Cocianni, Maria Perotto, Giuseppe Barone, Marco Merlo, Cristiana Vitale, Giuseppe Massimo Claudio
-
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Muthiah Vaduganathan, Brian L. Claggett, Carolyn S.P. Lam, Bertram Pitt, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Akshay S. Desai, Pardeep S. Jhund, Prabhakar Viswanathan, Antonieta Bomfim Wirtz, Patrick Schloemer, James Lay‐Flurrie, John J.V. McMurray, Scott D. Solomon
AimSteroidal mineralocorticoid receptor antagonists (MRAs), spironolactone and eplerenone, are strongly recommended in the treatment of patients with chronic heart failure (HF) with reduced left ventricular ejection fraction (LVEF), but the balance of efficacy and safety in those with higher LVEF has not been well established. Broad use of steroidal MRAs has further been limited in part due to safety
-
404‐error “Disease not found”: Unleashing the translational potential of ‐omics approaches beyond traditional disease classification in heart failure research Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Antonio Esquivel Gaytan, Nils Bomer, Niels Grote Beverborg, Peter van der Meer
The emergence of personalized medicine, facilitated by the progress in ‐omics technologies, has initiated a new era in medical diagnostics and treatment. This review examines the potential of ‐omics approaches in heart failure, a condition that has not yet fully capitalized on personalized strategies compared to other medical fields like cancer therapy. Here, we argue that integrating multi‐omics technology
-
Measuring congestion with a non‐invasive monitoring device in heart failure and haemodialysis: CONGEST‐HF Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 James P. Curtain, Atefeh Talebi, Alasdair McIntosh, Alex McConnachie, Joanne O'Donnell, Paul Welsh, Joanna Osmanska, Matthew M.Y. Lee, Piotr Sonecki, Tony Akl, Joohyun Seo, Venugopal Gopinathan, Jed Hurwitz, Srikanth Thiagarajan, Stephen Pettit, Paul R. Kalra, Rajan K. Patel, Patrick B. Mark, Ninian N. Lang, John J.V. McMurray, Mark C. Petrie, Roy S. Gardner, Pardeep S. Jhund
-
Renal function and natriuresis‐guided diuretic therapy – a pre‐specified analysis from the PUSH‐AHF trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-12 Kevin Damman, Iris E. Beldhuis, Peter van der Meer, Jan A. Krikken, Jenifer E. Coster, Wybe Nieuwland, Dirk J. van Veldhuisen, Adriaan A. Voors, Jozine M. ter Maaten
-
Contemporary guideline‐directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE‐HF study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-12 Jishnu Malgie, Mariëlle I. Wilde, Pascal R.D. Clephas, Mireille E. Emans, Stefan Koudstaal, Jeroen Schaap, Arend Mosterd, Jan van Ramshorst, Alexander J. Wardeh, Sandra van Wijk, Mieke van den Heuvel, Eric Wierda, C. Jan Willem Borleffs, Colette Saraber, Saskia L.M.A. Beeres, Roland van Kimmenade, Wouter Jansen Klomp, Robert Denham, Carlos A. da Fonseca, IJsbrand T. Klip, Olivier C. Manintveld, Robert
-
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-11 Scott D. Solomon, John W. Ostrominski, Muthiah Vaduganathan, Brian Claggett, Pardeep S. Jhund, Akshay S. Desai, Carolyn S.P. Lam, Bertram Pitt, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Imran Zainal Abidin, Marco Antonio Alcocer‐Gamba, John J. Atherton, Johann Bauersachs, Chang‐Sheng Ma, Chern‐En Chiang, Ovidiu Chioncel, Vijay Chopra, Josep Comin‐Colet, Gerasimos Filippatos, Cândida
-
New York Heart Association functional class and implantable cardioverter‐defibrillator in non‐ischaemic heart failure with reduced ejection fraction: Extended follow‐up of the DANISH trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-11 Munise N. Karacan, Seiko N. Doi, Adelina Yafasova, Jens Jakob Thune, Jens C. Nielsen, Jens Haarbo, Niels E. Bruun, Finn Gustafsson, Hans Eiskjær, Christian Hassager, Jesper H. Svendsen, Dan E. Høfsten, Steen Pehrson, Lars Køber, Jawad H. Butt
-
Sacubitril/valsartan and cardiovascular biomarkers among patients with recent COVID‐19 infection: The PARACOR‐19 randomized clinical trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-11 Stephen J. Greene, RaKavius Chambers, Joseph B. Lerman, Josephine Harrington, Christopher R deFilippi, David C. Wendell, Han W. Kim, Cynthia L. Green, Javed Butler, G. Michael Felker
AimsThe PARACOR‐19 randomized controlled trial (RCT) was designed to examine the effects of sacubitril/valsartan on markers of cardiac injury, inflammation, structure, and function among patients who have recovered from acute coronavirus disease 2019 (COVID‐19) infection.Methods and resultsPARACOR‐19 was a single‐centre, double‐blind RCT of patients with cardiovascular risk factors and a history of
-
Improvements in quality of heart failure randomized controlled trials: Progress and persisting challenges! Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-10 Amr Abdin, Saarraaken Kulenthiran
-
Critical re‐evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-10 Milton Packer, Stefan D. Anker, Javed Butler, John G.F. Cleland, Paul R. Kalra, Robert J. Mentz, Piotr Ponikowski, Khawaja M. Talha
According to current guidelines, iron deficiency is defined by a serum ferritin level <100 ng/ml or a transferrin saturation (TSAT) <20% if the serum ferritin level is 100–299 μg/L. These criteria were developed to encourage the use of intravenous iron as an adjunct to erythropoiesis‐stimulating agents in the treatment of renal anaemia. However, in patients with heart failure, these criteria are not
-
Impact of heart failure hospitalizations on clinical outcomes after mitral transcatheter edge‐to‐edge repair: Results from the EXPAND study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-10 Mirjam Kessler, Wolfgang Rottbauer, Ralph Stephan von Bardeleben, Carmelo Grasso, Philipp Lurz, Paul Mahoney, Matthew Price, Mathew Williams, Paolo Denti, Rodrigo Estevez‐Loureiro, Saibal Kar, Francesco Maisano
-
Iron homeostasis, recycling and vulnerability in the stressed kidney: A neglected dimension of iron‐deficient heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-10 Milton Packer
The available evidence suggests that the kidney may contribute importantly to the development of an iron deficiency state in patients with heart failure and may be injured by therapeutic efforts to achieve iron repletion. The exceptional workload of the proximal renal tubule requires substantial quantities of iron for ATP synthesis, which it derives from Fe3+ bound to transferrin in the bloodstream
-
Reduced congestion and improved response to a fluid/sodium challenge in chronic heart failure patients after initiation of sacubitril/valsartan: The NATRIUM‐HF study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-09 Alexandre Mebazaa, Beth A. Davison, Jan Biegus, Christopher Edwards, Gillian Murtagh, Christos Varounis, Hamlet Hayrapetyan, Hamayak Sisakian, Victor R. Ter‐Grigoryan, Koji Takagi, Maria Novosadova, Piotr Ponikowski, Gad Cotter
AimsThe effects of initiating sacubitril/valsartan in patients with stable heart failure with reduced ejection fraction (HFrEF) on response to fluid and sodium expansion are unknown.Methods and resultsWe have explored changes in natriuresis, diuresis, and congestion in response to the administration of intravenous fluid/sodium load in patients with HFrEF before as compared to after the initiation of
-
Guideline‐directed medical therapy in patients with heart failure with preserved ejection fraction and polypharmacy: Do not be afraid Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-08 Husam M. Salah, Marat Fudim
-
Metabolomics to predict heart failure development: A new frontier? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-08 Giorgia Panichella, Daniela Tomasoni, Alberto Aimo
-
Echocardiographic predictors of cardiovascular outcome in heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-08 Nelson Wang, Phidias Rueter, Melvin Ng, Sashiruben Chandramohan, Thomas Hibbert, John F. O'Sullivan, David Kaye, Sean Lal
AimsThe optimal echocardiographic predictors of cardiovascular outcome in heart failure (HF) with preserved ejection fraction (HFpEF) are unknown. We aimed to identify independent echocardiographic predictors of cardiovascular outcome in patients with HFpEF.Methods and resultsSystematic literature search of three electronic databases was conducted from date of inception until November 2022. Hazard
-
Correction to “Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction” Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-07
Chandramouli C, Ting TW, Tromp J, Agarwal A, Svedlund S, Saraste A, et al. Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2022;24:681–684. https://doi.org/10.1002/ejhf.2435 Within the abstract, in the Methods and Results section (2nd last line) P13K is incorrect (typo), it should read
-
Under pressure: Advances in device‐based heart failure therapy for patients with preserved or mildly reduced ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-03 Lukas Stolz, Jörg Hausleiter
-
Is it worth tying the knot? The lifelong commitment between heart failure patients and pulmonary artery pressure monitoring Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-03 Emil Wolsk
-
Identification and outcomes of KDIGO‐defined chronic kidney disease in 1.4 million U.S. Veterans with heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-03 Samir S. Patel, Venkatesh K. Raman, Sijian Zhang, Prakash Deedwania, Qing Zeng‐Treitler, Wen‐Chih Wu, Phillip H. Lam, George Bakris, Hans Moore, Paul A. Heidenreich, Janani Rangaswami, Charity J. Morgan, Yan Cheng, Helen M. Sheriff, Charles Faselis, Ravindra L. Mehta, Stefan D. Anker, Gregg C. Fonarow, Ali Ahmed
-
Tailored immunosuppression in biopsy‐proven immune‐mediated myocarditis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-03 Petr Kuchynka, Jan Krejci, Tomas Palecek
-
Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-03 Mingming Yang, Toru Kondo, Atefeh Talebi, Pardeep S. Jhund, Kieran F. Docherty, Brian L. Claggett, Muthiah Vaduganathan, Erasmus Bachus, Adrian F. Hernandez, Carolyn S.P. Lam, Silvio E. Inzucchi, Felipe A. Martinez, Rudolf A. de Boer, Mikhail N. Kosiborod, Akshay S. Desai, Lars Køber, Piotr Ponikowski, Marc S. Sabatine, Scott D. Solomon, John J.V. McMurray
-
Use of medical therapy and risk of clinical events according to frailty in heart failure patients – A real‐life cohort study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-03 Deewa Zahir Anjum, Jarl E. Strange, Emil Fosbøl, Caroline Hartwell Garred, Mariam Elmegaard, Charlotte Andersson, Pardeep S. Jhund, John J.V. McMurray, Mark C. Petrie, Lars Kober, Morten Schou
AimsAlthough recent randomized clinical trials have demonstrated the advantages of heart failure (HF) therapy in both frail and not frail patients, there is insufficient information on the use of HF therapy based on frailty status in a real‐world setting. The aim was to examine how frailty status in HF patients associates with use of HF therapy and with clinical outcomes.Methods and resultsPatients
-
Seeking ways to address non‐cardiovascular death in patients with heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-02 Yudai Fujimoto, Yuya Matsue
-
Sex differences in the prognostic role of achieving target doses of heart failure medications: Data from the Swedish Heart Failure Registry Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-02 Amerigo Ferrari, Davide Stolfo, Alicia Uijl, Nicola Orsini, Lina Benson, Gianfranco Sinagra, Peter Mol, Sieta T. de Vries, Ulf Dahlström, Giuseppe Rosano, Lars H. Lund, Gianluigi Savarese
-
Letter regarding the article ‘Use of natriuretic peptides and echocardiography for diagnosing heart failure’ Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-30 Yang‐Chi Lin, Yi‐Hsuan Sung, Chieh‐Hsuan Tsai
-
Letting go of restraint: Tricuspid valve intervention in heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-29 Vishal N. Rao, Elie Kozaily, Ryan J. Tedford
-
Obese or lean: Whom to prescribe sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-29 Kseniya Halavina, Philipp E. Bartko, Christian Nitsche
-
Pulmonary congestion in patients with pulmonary arterial hypertension? New insights from lung ultrasound Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-29 Elke Platz, David Systrom, Jane A. Leopold
-
Subclinical systolic dysfunction in genotype‐positive phenotype‐negative relatives of dilated cardiomyopathy patients: A systematic review and meta‐analysis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-29 Andrea Faggiano, Elisa Gherbesi, Eleonora Gnan, Alessia Paldino, Marco Merlo, Gianfranco Sinagra, Stefano Carugo
The absence of left ventricular (LV) dilatation and systolic dysfunction, as assessed by LV ejection fraction (LVEF), in family members of genetically confirmed dilated cardiomyopathy (DCM) patients, carrying pathogenic (P) or likely pathogenic (LP) familial gene variants categorizes them as a subgroup called genotype-positive phenotype-negative (GEN+ PHEN−). Identifying GEN+ PHEN− who are at the highest
-
Association of sodium–glucose cotransporter 2 inhibitors with changes in comprehensive geriatric assessment in elderly diabetic patients with heart failure: Data from MAGIC‐HF Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-29 Giuseppe Armentaro, Velia Cassano, Valentino Condoleo, Marcello Magurno, Marcello Divino, Carlo Alberto Pastura, Sofia Miceli, Raffaele Maio, Franco Arturi, Marta Letizia Hribal, Antonio Brunetti, Giorgio Sesti, Giuseppe Massimo Claudio Rosano, Angela Sciacqua
Heart failure (HF) represents the primary cause of hospitalization, disability, mortality, and healthcare costs in elderly patients.1 The comprehensive geriatric assessment (CGA) is a multidimensional tool for assessing cognitive function, mood symptoms, and functional abilities that can predict short- and long-term mortality in patients with HF, despite some limitations in different clinical domains
-
Differential sex‐related effect of left ventricular ejection fraction trajectory on the risk of mortality and heart failure readmission following hospitalization for acute heart failure: A longitudinal study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-29 Eduardo Núñez, Enrique Santas, Hector Merenciano, Miguel Lorenzo‐Hernández, Anna Mollar, Gema Miñana, Patricia Palau, Laura Fuertes, Ernesto Valero, Rafael de la Espriella, Vicent Bodí, Juan Sanchis, Antoni Bayés‐Genís, Julio Núñez
-
Multidisciplinary care of peripartum heart failure: A scientific statement of the Heart Failure Association of the ESC Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-29 Amina Rakisheva, Karen Sliwa, Johann Bauersachs, Sophie Van Linthout, Vijay K. Chopra, Antoni Bayes‐Genis, Franca Fruzzetti, Antonio Cannatà, Benjamin Deniau, Alexandre Mebazaa, Gianluigi Savarese, Robin Ray, Cristiana Vitale, Marco Metra, Giuseppe M.C. Rosano
Heart failure is the most common cardiovascular complication during pregnancy and the postpartum period. It is associated with increased risk of maternal morbidity and mortality as well as potentially life‐threatening foetal pathology. Management of heart failure in pregnancy requires expert knowledge of cardiovascular disease as well as obstetrics which underscores the importance of multidisciplinary
-
Baroreceptors as a target of device‐based neuromodulation in heart failure: Long‐term outcomes Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-25 Guido Grassi, Raffaella Dell'Oro, Fosca Quarti‐Trevano
-
Interatrial shunting as a treatment for heart failure: Where do we stand? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-25 Thomas M. Gorter, Elke S. Hoendermis, Dirk J. van Veldhuisen
-
Randomized investigation of the MitraClip device in heart failure: Design and rationale of the RESHAPE‐HF2 trial design Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-24 Stefan D. Anker, Tim Friede, Ralph Stephan von Bardeleben, Javed Butler, Kaneez Fatima, Monika Diek, Jutta Heinrich, Gerd Hasenfuß, Wolfgang Schillinger, Piotr Ponikowski
AimsThe safety and effectiveness of the MitraClip device to treat functional mitral regurgitation (FMR) has been tested in previous clinical trials yielding somewhat heterogeneous results in heart failure (HF) patients. Over time, the MitraClip device system has been modified and clinical practice evolved to consider also less severely diseased HF patients with FMR for this therapeutic option. The
-
Is it NICE to measure natriuretic peptides after a hospitalization for heart failure? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-24 Matteo Pagnesi, Marianna Adamo, Marco Metra
-
Follow the EMPULSE: In‐hospital initiation of empagliflozin for heart failure across the spectrum of left ventricular ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-24 Tann Lien, Kishan Srikanth, Andrew P. Ambrosy
-
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-19 Pietro Ameri, Valentina Mercurio, Piero Pollesello, Markus S. Anker, Johannes Backs, Antoni Bayes-Genis, Barry A. Borlaug, Daniel Burkhoff, Sergio Caravita, Stephen Y. Chan, Frances de Man, George Giannakoulas, Aránzazu González, Marco Guazzi, Paul M. Hassoun, Anna R. Hemnes, Cristoph Maack, Brendan Madden, Vojtech Melenovsky, Oliver J. Müller, Zoltan Papp, Soni Savai Pullamsetti, Peter P. Rainer,
Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH-LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH-LHF, despite the high number of drugs tested so far. This scientific document addresses the
-
Role of stiff atrium in elucidating diastolic dysfunction in Fontan circulation. Letter regarding the article ‘Exercise catheterization in adults post‐Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology’ Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-19 Makoto Takei
-
Long-term efficacy and safety of tailored immunosuppressive therapy in immune-mediated biopsy-proven myocarditis: A propensity-weighted study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-17 Alida Linda Patrizia Caforio, Andrea Silvio Giordani, Anna Baritussio, Davide Marcolongo, Cristina Vicenzetto, Giuseppe Tarantini, Massimo Napodano, Giuseppe Toscano, Dario Gregori, Gloria Brigiari, Patrizia Bartolotta, Elisa Carturan, Monica De Gaspari, Stefania Rizzo, Cristina Basso, Sabino Iliceto, Renzo Marcolongo
-
Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-17 Rahul Aggarwal, Deepak L. Bhatt, Michael Szarek, Lawrence A. Leiter, Christopher P. Cannon, Renato D. Lopes, Michael J Davies, Phillip Banks, Bertram Pitt, Ph. Gabriel Steg
Sotagliflozin is a dual sodium–glucose cotransporter (SGLT) 1 and SGLT2 inhibitor that reduces heart failure (HF) outcomes in adults with type 2 diabetes and high cardiovascular (CV) risk.1, 2 Understanding the time-to-benefit with therapy can inform the urgency with which to prescribe. SCORED was a randomized, double-blind study of patients with type 2 diabetes (glycated haemoglobin ≥7%), chronic
-
Mitral regurgitation in heart failure with preserved ejection fraction: The interplay of valve, ventricle, and atrium Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-17 Sebastiaan Dhont, Gitte van den Acker, Tim van Loon, Frederik H. Verbrugge, Jan Verwerft, Sébastien Deferm, Timothy W. Churchill, Wilfried Mullens, Joost Lumens, Philippe B. Bertrand
-
The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: Is the time ripe for clinical use of sodium–glucose cotransporter 2 inhibitors? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-16 Aldostefano Porcari, Marianna Fontana
-
Reporting quality of heart failure randomized controlled trials 2000–2020: Temporal trends in adherence to CONSORT criteria Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-16 Mohamed B. Jalloh, Veronica A. Bot, Cristiana Z. Borjaille, Lehana Thabane, Guowei Li, Javed Butler, Faiez Zannad, Christopher B. Granger, Harriette G.C. Van Spall
-
Serum metabolomics improves risk stratification for incident heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-16 Rafael R. Oexner, Hyunchan Ahn, Konstantinos Theofilatos, Ravi A. Shah, Robin Schmitt, Philip Chowienczyk, Anna Zoccarato, Ajay M. Shah
-
Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long‐term outcomes Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-12 Michael R. Zile, JoAnn Lindenfeld, Fred A. Weaver, Faiez Zannad, Elizabeth Galle, Tyson Rogers, William T. Abraham
AimsCarotid baroreflex activation therapy (BAT) restores baroreflex sensitivity and modulates the imbalance in cardiac autonomic function in patients with heart failure with reduced ejection fraction (HFrEF). We tested the hypothesis that treatment with BAT significantly reduces cardiovascular mortality and heart failure morbidity and provides long‐term safety and sustainable symptomatic improvement
-
Reply to ‘The pharmacist ally in heart failure: Useful when involved’ Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-12 Craig J. Beavers, Deepak L. Bhatt, Gad Gotter
-
Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-12 Wilfried Mullens, Kevin Damman, Sebastiaan Dhont, Debasish Banerjee, Antoni Bayes‐Genis, Antonio Cannata, Ovidiu Chioncel, Maja Cikes, Justin Ezekowitz, Andreas J. Flammer, Pieter Martens, Alexandre Mebazaa, Robert J. Mentz, Òscar Miró, Brenda Moura, Julio Nunez, Jozine M. Ter Maaten, Jeffrey Testani, Roland van Kimmenade, Frederik H. Verbrugge, Marco Metra, Giuseppe M.C. Rosano, Gerasimos Filippatos
Sodium and fluid restriction has traditionally been advocated in patients with heart failure (HF) due to their sodium and water avid state. However, most evidence regarding the altered sodium handling, fluid homeostasis and congestion‐related signs and symptoms in patients with HF originates from untreated patient cohorts and physiological investigations. Recent data challenge the beneficial role of
-
Left atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1‐year results Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-12 Marcus A. Urey, Benjamin Hibbert, Ulrich Jorde, Peter Eckman, Trevor Simard, Marino Labinaz, Babak Nazer, Mark Wiley, Bhanu Gupta, Andrew Sauer, Hirak Shah, Paul Sorajja, Andres M. Pineda, Emil Missov, Ehtisham Mahmud, Rami Kahwash, Scott Lilly, Azeem Latib, Sandhya Murthy, Neil Fam, Santiago Garcia, Eugene S. Chung, Liviu Klein, Richard Cheng, Brian A. Houston, Nicholas S. Amoroso, Lee Chang, Sameer
AimsPatients with heart failure and mildly reduced or preserved ejection fraction have limited therapeutic options. The ALT‐FLOW Early Feasibility Study evaluated safety, haemodynamics and outcomes for the APTURE transcatheter shunt system, a novel left atrium to coronary sinus shunt in these patients.Methods and resultsSafety and shunt implantation success was evaluated for all 116 enrolled patients
-
Impact of guideline‐directed medical therapy on systolic blood pressure and cardiovascular outcomes in patients with heart failure and low blood pressure: A systematic review and meta‐analysis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-12 Jingwei Li, Yunlong Chen, Yi Wang, Xiaoyan Liu, Ping Li, Yongming He, Yang Hao, Lan Huang, Jun Jin, Jiang Wang, Craig Anderson
AimsExisting research indicates that patients with heart failure (HF) may have restricted access to guideline‐directed medical therapy (GDMT) when their blood pressure (BP) is comparatively low. However, recent clinical trials suggest that HF patients with low BP could still benefit from certain HF medications, which have a minimal impact on BP. This systematic review and meta‐analysis was conducted